Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations
NCT04511533
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
101
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
DRUG:
Dacomitinib
Sponsor
Pfizer